Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-105939
Filing Date
2025-08-08
Accepted
2025-08-08 16:36:01
Documents
64
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q etnb-20250630.htm   iXBRL 10-Q 2264492
2 EX-10.1 etnb-ex10_1.htm EX-10.1 16344
3 EX-10.2 etnb-ex10_2.htm EX-10.2 40723
4 EX-31.1 etnb-ex31_1.htm EX-31.1 16189
5 EX-31.2 etnb-ex31_2.htm EX-31.2 16201
6 EX-32 etnb-ex32.htm EX-32 17180
7 GRAPHIC img164203169_0.jpg GRAPHIC 12456
  Complete submission text file 0000950170-25-105939.txt   8954615

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT etnb-20250630.xsd EX-101.SCH 1128205
67 EXTRACTED XBRL INSTANCE DOCUMENT etnb-20250630_htm.xml XML 1705343
Mailing Address 655 MONTGOMERY STREET SUITE 1500 SAN FRANCISCO CA 94111
Business Address 655 MONTGOMERY STREET SUITE 1500 SAN FRANCISCO CA 94111 (415) 432-9270
89bio, Inc. (Filer) CIK: 0001785173 (see all company filings)

EIN.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39122 | Film No.: 251199028
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)